BridgeBio Reports Strong Revenue Growth for Attruby in Q4 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 Jan 26
Source: Globenewswire
BridgeBio Pharma Inc. shares rose 3.87% as the company reached a 52-week high.
The surge in stock price follows BridgeBio's report of $146 million in net product revenue for Attruby (acoramidis) in Q4 2025, reflecting strong market demand and a significant increase in prescriptions. The company also announced a new TTR amyloid depleter antibody program expected to enter clinical trials between 2027 and 2028, which could further enhance its market position.
This strong financial performance and the promising pipeline developments position BridgeBio favorably in the competitive landscape of cardiac amyloidosis treatments.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
Current: 79.100
Low
69.00
Averages
87.63
High
100.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
